The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Aureon Laboratories launched Prostate Px a test that determines risk for prostate cancer recurrence and clinical failure (distant metastasis). The test is based on Aureon's Systems Pathology platform, which integrates clinical history, tissue pathology and molecular analyses performed using the formalin-fixed, paraffin-embedded tissue stored locally by the hospital pathology department.
CytoCore acquired a license for apoptosis biomarker CG15 from Dr. George Gorodeski, the inventor, and University Hospitals Cleveland. CGI5 can distinguish pre-cancerous and cancer cells from normal cells. CGI5 tracks the changes in the dying or apoptotic process.
GeneFluidics is commercializing an electrochemical DNA biosensors to identify gram negative bacteria in urine as a test for UTI. The biosensor converts nucleic acid sequences into electrical signals.
Ikonisys received FDA clearance to market the Ikoniscope fastFISH amnio Test System, an automated scanning microscope coupled with image analysis, acquisition and display functions. It is intended to detect amniotic cells stained by FISH using commercially available direct- labeled DNA probes or chromosomes X, Y, 13, 18 and 21.
Luminex signed a licensing agreement with the Massachusetts Institute of Technology for non- exclusive intellectual property rights necessary to develop and commercialize microRNA assays and related products.
NorDiag ASA has incorporated Transgenomic's WAVE System in its Genefec test to detect mutations associated with early development of gastrointestinal cancers such as colorectal cancer.
![[Page Banner Image]](images/hmole.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
